Gout (Hyperuricemia and Acute/Chronic Gouty Arthritis) Treatment
Covered by Aetna in California

Acute flare: colchicine 1.2mg at onset then 0.6mg 1 hour later (ACR 2020 'low-dose' regimen), then 0.6mg twice daily until flare resolves; OR indomethacin 50mg three times daily × 5–7 days (avoid in elderly patients >70 and patients with eGFR <50); prednisone 40mg × 5 days (if NSAIDs and colchicine contraindicated). Chronic ULT: allopurinol 100mg daily starting dose, titrated in 100mg increments every 4 weeks to serum uric acid target <6.0 mg/dL (or <5 mg/dL with tophi); maximum dose 800mg/day (adjusted to eGFR)

Febuxostat 40–80mg daily for patients with documented allopurinol intolerance or HLA-B*5801 allele carrier status (higher hypersensitivity risk in East Asian patients — screen before allopurinol in Han Chinese, Korean, Thai patients); probenecid 500–1000mg twice daily (uricosuric — avoid with eGFR <50 or urolithiasis history); losartan 50mg daily (uricosuric antihypertensive — preferred diuretic substitute if patient is on thiazides, per ACR guidance); colchicine 0.6mg daily for 3–6 months as anti-inflammatory prophylaxis when initiating ULT to prevent paradoxical flares

Yes — allopurinol, colchicine (generic), indomethacin, and probenecid are all Tier 1 generics on Aetna CA commercial plans, typically $4–$25/month. Febuxostat requires step therapy through allopurinol first on most Aetna CA plans; if allopurinol intolerance or contraindication is documented, PA can be obtained. NSAIDs and prednisone for acute flares are Tier 1.

ACR 2020 Guideline conditionally recommends ULT initiation for patients with ≥2 gout flares per year, tophi, radiographic joint damage, or CKD ≥stage 3. Treat-to-target serum uric acid <6 mg/dL (or <5 mg/dL with tophi) is the ACR/AHA standard. Febuxostat carries an FDA Boxed Warning (2019) for increased cardiovascular mortality compared to allopurinol in patients with established CVD — febuxostat reserved for allopurinol failures only. ACC/AHA 2024 dyslipidemia guidelines note that gout and hyperuricemia are associated with increased ASCVD risk, and antihypertensive selection should favor losartan (uricosuric) over thiazides (hyperuricemic) in gout patients. Lab monitoring: baseline renal function (eGFR), uric acid, CBC before allopurinol start; recheck uric acid 4 weeks after each dose increment.

On most Aetna CA commercial plans, febuxostat requires step therapy — documented trial and inadequate response to allopurinol, or a documented contraindication or intolerance to allopurinol. This is consistent with the FDA's 2019 Boxed Warning restricting febuxostat to patients who have failed allopurinol, due to higher cardiovascular mortality risk in patients with established heart disease. Exceptions include patients of East Asian ancestry with the HLA-B*5801 allele (at high risk of allopurinol hypersensitivity syndrome), where febuxostat is the preferred first-line ULT. Dr. Bhavsar can document allopurinol intolerance or contraindication to support a PA for febuxostat.

Yes. Colchicine 0.6mg daily or every other day for 3–6 months as prophylaxis when starting or adjusting ULT is appropriate for telehealth prescription. Generic colchicine is Tier 1 on Aetna CA plans (~$10–$25/month). Dr. Bhavsar will review your current allopurinol or febuxostat dose, most recent uric acid level, and renal function (colchicine dose-adjusts at eGFR <30 and is contraindicated below eGFR 15). Important: colchicine has significant drug interactions — strong CYP3A4 inhibitors (clarithromycin, certain antifungals) and P-glycoprotein inhibitors markedly increase colchicine toxicity; Dr. Bhavsar reviews your full medication list before prescribing.

Thiazide and loop diuretics are among the most common drug-induced causes of hyperuricemia and gout. ACR 2020 guidelines conditionally recommend switching hydrochlorothiazide to an alternative antihypertensive — preferably losartan (which has a mild uricosuric effect) or a calcium channel blocker — in gout patients when the hypertension indication allows. Dr. Bhavsar can adjust your antihypertensive regimen during your gout visit if this substitution is medically appropriate, helping address both blood pressure control and uric acid burden with one change. Losartan is a Tier 1 generic on all Aetna CA plans.

Yes. Aetna commercial plans cover telehealth visits for Gout (Hyperuricemia and Acute/Chronic Gouty Arthritis) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your gout treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your gout treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.